MAP2K7 and cancer: Previous reports show that inhibition of MEK kinase by MEK inhibitors like selumetinib in RAS mutated cancer cell lines triggers reactivation of CRAF leading to MEK binding, phosphorylation, and a decrease in sensitivity to MEK inhibitors (Lito et al. 2014).